Anne Margarita Dyrhol-Riise

  • Professor II UiO, Consultant; PhD
  • +47 22 11 73 97
 

Publications 2024

Alirezaylavasani A, Skeie LG, Egner IM, Chopra A, Dahl TB, Prebensen C, Vaage JT, Halvorsen B, Lund-Johansen F, Tonby K, Reikvam DH, Stiksrud B, Holter JC, Dyrhol-Riise AM, Munthe LA, Kared H (2024)
Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections
NPJ Vaccines, 9 (1), 185
DOI 10.1038/s41541-024-00972-3, PubMed 39384763

Alonso-Rodríguez N, Vianello E, van Veen S, Jenum S, Tonby K, van Riessen R, Lai X, Mortensen R, Ottenhoff THM, Dyrhol-Riise AM (2024)
Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy
Front Immunol, 15, 1350593
DOI 10.3389/fimmu.2024.1350593, PubMed 38433842

Barratt-Due A, Pettersen K, Børresdatter-Dahl T, Holter JC, Grønli RH, Dyrhol-Riise AM, Lerum TV, Holten AR, Tonby K, Trøseid M, Skjønsberg OH, Granerud BK, Heggelund L, Kildal AB, Schjalm C, Aaløkken TM, Aukrust P, Ueland T, Mollnes TE, Halvorsen B, NOR‐Solidarity study groupThe Norwegian SARS‐CoV‐2 study group (2024)
Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients
J Intern Med, 296 (1), 80-92
DOI 10.1111/joim.13783, PubMed 38539241

Halvorsen B, Viermyr HK, Ueland T, Sagen EL, Michelsen AE, Bjerkeli V, Nor-Solidarity Study Group, Tveita AA, Henriksen KN, Kåsine T, Dyrhol-Riise AM, Trøseid M, Dahl TB, Aukrust P, Gregersen I (2024)
IL-22 is increased in hospitalized patients with COVID-19 and associates with cardiac involvement
J Infect, 89 (1), 106176
DOI 10.1016/j.jinf.2024.106176, PubMed 38719108

Hites M, Massonnaud CR, Lapique EL, Belhadi D, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Moing VL, Piroth L, Sellier P et al. (2024)
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
J Infect, 88 (3), 106120
DOI 10.1016/j.jinf.2024.106120, PubMed 38367705

Hoel H, Dahl TB, Yang K, Skeie LG, Michelsen AE, Ueland T, Damås JK, Dyrhol-Riise AM, Fevang B, Yndestad A, Aukrust P, Trøseid M, Sandanger Ø (2024)
Chronic HIV Infection Increases Monocyte NLRP3 Inflammasome-Dependent IL-1α and IL-1β Release
Int J Mol Sci, 25 (13)
DOI 10.3390/ijms25137141, PubMed 39000248

Mortensen R, Clemmensen HS, Woodworth JS, Therkelsen ML, Mustafa T, Tonby K, Jenum S, Agger EM, Dyrhol-Riise AM, Andersen P (2024)
Author Correction: Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice
Commun Biol, 7 (1), 662
DOI 10.1038/s42003-024-06260-z, PubMed 38811662

Murphy SL, Balzer NR, Ranheim T, Sagen EL, Huse C, Bjerkeli V, Michelsen AE, Finbråten AK, Heggelund L, Dyrhol-Riise AM, Tveita A, Holten AR, Trøseid M, Ueland T, Ulas T, Aukrust P, Barratt-Due A, Halvorsen B, Dahl TB (2024)
Extracellular matrix remodelling pathway in peripheral blood mononuclear cells from severe COVID-19 patients: an explorative study
Front Immunol, 15, 1379570
DOI 10.3389/fimmu.2024.1379570, PubMed 38957465

Nore KG, Louet C, Bugge M, Gidon A, Jørgensen MJ, Jenum S, Dyrhol-Riise AM, Tonby K, Flo TH (2024)
The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth
J Infect Dis, 229 (3), 888-897
DOI 10.1093/infdis/jiad390, PubMed 37721470

Patrick-Brown TDJH, Barratt-Due A, Trøseid M, Dyrhol-Riise AM, Nezvalova-Henriksen K, Kåsine T, Aukrust P, Olsen IC, NOR Solidarity consortium (2024)
The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis
Commun Med (Lond), 4 (1), 231
DOI 10.1038/s43856-024-00650-4, PubMed 39533001

Viermyr HK, Halvorsen B, Sagen EL, Michelsen AE, Barrat-Due A, Kåsine T, Nezvalova-Henriksen K, Dyrhol-Riise AM, Nor‐Solidarity Consortium, Lerum TV, Müller F, Tonby K, Tveita A, Aukrust P, Trøseid M, Ueland T, Dahl TB (2024)
High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial
J Intern Med, 296 (3), 249-259
DOI 10.1111/joim.13820, PubMed 39011800

Publications 2023

Abdelhak A, Barba L, Romoli M, Benkert P, Conversi F, D'Anna L, Masvekar RR, Bielekova B, Prudencio M, Petrucelli L, Meschia JF, Erben Y, Furlan R, De Lorenzo R, Mandelli A, Sutter R, Hert L, Epple V, Marastoni D, Sellner J, Steinacker P, Aamodt AH, Heggelund L, Dyrhol-Riise AM, Virhammar J et al. (2023)
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis
J Neurol, 270 (7), 3315-3328
DOI 10.1007/s00415-023-11768-1, PubMed 37184659

Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, Denton PW, Nielsen H, Johansen IS, Benfield T, Leth S, Gerstoft J, Østergaard L, Schleimann MH, Olesen R, Støvring H, Vibholm L, Weis N, Dyrhol-Riise AM, Pedersen KBH, Lau JSY, Copertino DC, Linden N, Huynh TT, Ramos V et al. (2023)
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
Nat Med, 29 (10), 2547-2558
DOI 10.1038/s41591-023-02547-6, PubMed 37696935

Mohn KG, Bredholt G, Onyango TB, Brokstad KA, Zhou F, Holter JC, Tonby K, Dyrhol-Riise AM, Cox RJ, Bergen COVID-19 Research Group, Norwegian SARS-CoV-2 Study Group (2023)
SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity
J Infect, 87 (4), 346-349
DOI 10.1016/j.jinf.2023.05.023, PubMed 37295510

Nissen-Meyer LSH, Macpherson ME, Skeie LG, Hvalryg M, Llohn AH, Steinsvåg TT, Fenstad MH, Tveita A, Kristoffersen EK, Sundic T, Lund-Johansen F, Vaage JT, Flesland Ø, Dyrhol-Riise AM, Holter JC, Hervig TA, Fevang B (2023)
COVID-19 patients treated with convalescent plasma
Tidsskr Nor Laegeforen, 143 (11)
DOI 10.4045/tidsskr.22.0577, PubMed 37589359

Quiles-Jiménez A, Sousa MML, Huse C, Dyrhol-Riise AM, Holter JC, Christensen EE, Tonby K, Holten AR, Aukrust P, Bjørås M, Dahl TB, Halvorsen B (2023)
Severely ill COVID-19 patients have altered circulating levels of proteins controlling the epitranscriptome
J Infect, 86 (6), 593-595
DOI 10.1016/j.jinf.2023.03.002, PubMed 36889510

Trøseid M, Holter JC, Holm K, Vestad B, Sazonova T, Granerud BK, Dyrhol-Riise AM, Holten AR, Tonby K, Kildal AB, Heggelund L, Tveita A, Bøe S, Müller KE, Jenum S, Hov JR, Ueland T, Norwegian SARS-CoV-2 study group (2023)
Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19
Crit Care, 27 (1), 69
DOI 10.1186/s13054-023-04356-2, PubMed 36814280

Ueland T, Michelsen AE, Tveita AA, Kåsine T, Dahl TB, Finbråten AK, Holten AR, Skjønsberg OH, Mathiessen A, Henriksen KN, Trøseid M, Aaløkken TM, Halvorsen B, Dyrhol-Riise AM, Barratt-Due A, Aukrust P (2023)
Coagulopathy and adverse outcomes in hospitalized patients with COVID-19: results from the NOR-Solidarity trial
Res Pract Thromb Haemost, 8 (1), 102289
DOI 10.1016/j.rpth.2023.102289, PubMed 38292350

Ueland T, Äikäs LAO, Dahl TB, Gregersen I, Olsen MB, Michelsen A, Schanke Y, Holopainen M, Ruhanen H, Singh S, NOR-SOLIDARITY Consortium, Tveita AA, Finbråten AK, Heggelund L, Trøseid M, Dyrhol-Riise AM, Nyman TA, Holven KB, Öörni K, Aukrust P, Halvorsen B (2023)
Low-density lipoprotein particles carrying proinflammatory proteins with altered aggregation pattern detected in COVID-19 patients 3 months after hospitalization
J Infect, 86 (5), 489-492
DOI 10.1016/j.jinf.2023.02.024, PubMed 36822413

Publications 2022

Chendi BH, Jooste T, Scriba TJ, Kidd M, Mendelsohn S, Tonby K, Walzl G, Dyrhol-Riise AM, Chegou NN (2022)
Utility of a three-gene transcriptomic signature in the diagnosis of tuberculosis in a low-endemic hospital setting
Infect Dis (Lond), 55 (1), 44-54
DOI 10.1080/23744235.2022.2129779, PubMed 36214761

Christensen EE, Binde C, Leegaard M, Tonby K, Dyrhol-Riise AM, Kvale D, Amundsen EK, Holten AR (2022)
DIAGNOSTIC ACCURACY AND ADDED VALUE OF INFECTION BIOMARKERS IN PATIENTS WITH POSSIBLE SEPSIS IN THE EMERGENCY DEPARTMENT
Shock, 58 (4), 251-259
DOI 10.1097/SHK.0000000000001981, PubMed 36130401

Degenhardt F, Ellinghaus D, Juzenas S, Lerga-Jaso J, Wendorff M, Maya-Miles D, Uellendahl-Werth F, ElAbd H, Rühlemann MC, Arora J, Özer O, Lenning OB, Myhre R, Vadla MS, Wacker EM, Wienbrandt L, Blandino Ortiz A, de Salazar A, Garrido Chercoles A, Palom A, Ruiz A, Garcia-Fernandez AE, Blanco-Grau A, Mantovani A, Zanella A et al. (2022)
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
Hum Mol Genet, 31 (23), 3945-3966
DOI 10.1093/hmg/ddac158, PubMed 35848942

Gohli J, Brantsæter AB, Bøifot KO, Grub C, Granerud BK, Holter JC, Riise AMD, Smedholen MF, Dybwad M (2022)
SARS-CoV-2 in the Air Surrounding Patients during Nebulizer Therapy
Can J Infect Dis Med Microbiol, 2022, 9297974
DOI 10.1155/2022/9297974, PubMed 36213437

Gregersen I, Ueland T, Holter JC, Olsen MB, Michelsen AE, Murphy SL, Tveita AA, Henriksen KN, Hoel H, Nordberg LB, Holten AR, Edvardsen T, Yang K, Heggelund L, Trøseid M, Müller F, Kildal AB, Dyrhol-Riise AM, Barratt-Due A, Dahl TB, Aukrust P, Halvorsen B, NOR-SOLIDARITY consortium, The Norwegian SARS-CoV-2 Study Group investigators (2022)
CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19
J Infect, 85 (6), 702-769
DOI 10.1016/j.jinf.2022.09.029, PubMed 36216188

Lekva T, Ueland T, Halvorsen B, Murphy SL, Dyrhol-Riise AM, Tveita A, Finbråten AK, Mathiessen A, Müller KE, Aaløkken TM, Skjønsberg OH, Lerum TV, Aukrust P, Dahl TB (2022)
Markers of cellular senescence is associated with persistent pulmonary pathology after COVID-19 infection
Infect Dis (Lond), 54 (12), 918-923
DOI 10.1080/23744235.2022.2113135, PubMed 35984738

Meyer-Myklestad MH, Medhus AW, Lorvik KB, Seljeflot I, Hansen SH, Holm K, Stiksrud B, Trøseid M, Hov JR, Kvale D, Dyrhol-Riise AM, Kummen M, Reikvam DH (2022)
Human Immunodeficiency Virus-Infected Immunological Nonresponders Have Colon-Restricted Gut Mucosal Immune Dysfunction
J Infect Dis, 225 (4), 661-674
DOI 10.1093/infdis/jiaa714, PubMed 33216130

Meyer-Myklestad MH, Medhus AW, Stiksrud B, Lorvik KB, Seljeflot I, Hansen SH, Holm K, Hov JR, Kvale D, Dyrhol-Riise AM, Kummen M, Trøseid M, Reikvam DH (2022)
Probiotics to HIV-Infected Immunological Nonresponders: Altered Mucosal Immunity and Microbial Diversity Restricted to Ileum
J Acquir Immune Defic Syndr, 89 (1), 77-86
DOI 10.1097/QAI.0000000000002817, PubMed 34878437

Murphy SL, Halvorsen B, Barratt-Due A, Dyrhol-Riise AM, Aukrust P, Trøseid M, Dahl TB (2022)
Remdesivir modifies interferon response in hospitalized COVID-19 patients
J Infect, 85 (5), 573-607
DOI 10.1016/j.jinf.2022.07.021, PubMed 35914611

Olsen MB, Huse C, de Sousa MML, Murphy SL, Sarno A, Obermann TS, Yang K, Holter JC, Jørgensen MJ, Christensen EE, Wang W, Ji P, Heggelund L, Hoel H, Dyrhol-Riise AM, Gregersen I, Aukrust P, Bjørås M, Halvorsen B, Dahl TB (2022)
DNA Repair Mechanisms are Activated in Circulating Lymphocytes of Hospitalized Covid-19 Patients
J Inflamm Res, 15, 6629-6644
DOI 10.2147/JIR.S379331, PubMed 36514358

Trøseid M, Dahl TB, Holter JC, Kildal AB, Murphy SL, Yang K, Quiles-Jiménez A, Heggelund L, Müller KE, Tveita A, Michelsen AE, Bøe S, Holten AR, Hoel H, Mathiessen A, Aaløkken TM, Fevang B, Granerud BK, Tonby K, Henriksen KN, Lerum TV, Müller F, Skjønsberg OH, Barratt-Due A, Dyrhol-Riise AM et al. (2022)
Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: Results from two Norwegian cohort studies
J Intern Med, 292 (5), 816-828
DOI 10.1111/joim.13549, PubMed 35982589

Tveita A, Murphy SL, Holter JC, Kildal AB, Michelsen AE, Lerum TV, Kaarbø M, Heggelund L, Holten AR, Finbråten AK, Müller KE, Mathiessen A, Bøe S, Fevang B, Granerud BK, Tonby K, Lind A, Dudman SG, Henriksen KN, Müller F, Skjønsberg OH, Trøseid M, Barratt-Due A, Dyrhol-Riise AM, Aukrust P et al. (2022)
High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19
J Infect Dis, 226 (12), 2150-2160
DOI 10.1093/infdis/jiac313, PubMed 35876699

Ueland T, Hausberg I, Mørtberg TV, Dahl TB, Lerum TV, Michelsen A, Ranheim T, Nezvalova Henriksen K, Dyrhol-Riise AM, Holme PA, Aaløkken TM, Skjønsberg OH, Barratt-Due A, Ahlén MT, Aukrust P, Halvorsen B (2022)
Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology
Platelets, 33 (4), 640-644
DOI 10.1080/09537104.2022.2042238, PubMed 35225150

Vestad B, Ueland T, Lerum TV, Dahl TB, Holm K, Barratt-Due A, Kåsine T, Dyrhol-Riise AM, Stiksrud B, Tonby K, Hoel H, Olsen IC, Henriksen KN, Tveita A, Manotheepan R, Haugli M, Eiken R, Berg Å, Halvorsen B, Lekva T, Ranheim T, Michelsen AE, Kildal AB, Johannessen A, Thoresen L et al. (2022)
Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations
J Intern Med, 291 (6), 801-812
DOI 10.1111/joim.13458, PubMed 35212063

Wæhre T, Tunheim G, Bodin JE, Laake I, Kvale D, Kran AB, Brekke H, Løken R, Oftung F, Mjaaland S, Dyrhol-Riise AM (2022)
Clinical characteristics and outcomes in hospitalized adult influenza patients: an observational study from Norway 2014-2018
Infect Dis (Lond), 54 (5), 367-377
DOI 10.1080/23744235.2021.2022196, PubMed 34983302

Publications 2021

Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Kildal AB, Berg Å, Johannessen A, Heggelund L, Dahl TB, Skåra KH, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR, Olsen RB et al. (2021)
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial
Ann Intern Med, 174 (9), 1261-1269
DOI 10.7326/M21-0653, PubMed 34251903

Chendi BH, Snyders CI, Tonby K, Jenum S, Kidd M, Walzl G, Chegou NN, Dyrhol-Riise AM (2021)
A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries
Front Immunol, 12, 608846
DOI 10.3389/fimmu.2021.608846, PubMed 33732236

Chendi BH, Tveiten H, Snyders CI, Tonby K, Jenum S, Nielsen SD, Hove-Skovsgaard M, Walzl G, Chegou NN, Dyrhol-Riise AM (2021)
CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries
J Infect, 83 (4), 433-443
DOI 10.1016/j.jinf.2021.07.036, PubMed 34333033

Christensen EE, Jørgensen MJ, Nore KG, Dahl TB, Yang K, Ranheim T, Huse C, Lind A, Nur S, Stiksrud B, Jenum S, Tonby K, Holter JC, Holten AR, Halvorsen B, Dyrhol-Riise AM (2021)
Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns
J Intern Med, 290 (3), 677-692
DOI 10.1111/joim.13310, PubMed 34080738

Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM (2021)
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
Nat Commun, 12 (1), 6774
DOI 10.1038/s41467-021-27029-6, PubMed 34811370

Jøntvedt Jørgensen M, Nore KG, Aass HCD, Layre E, Nigou J, Mortensen R, Tasken K, Kvale D, Jenum S, Tonby K, Dyrhol-Riise AM (2021)
Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
Front Cell Infect Microbiol, 11, 669623
DOI 10.3389/fcimb.2021.669623, PubMed 34307194

Kolberg ES, Wickstrøm K, Tonby K, Dyrhol-Riise AM, Holten AR, Amundsen EK (2021)
Serum ACE as a prognostic biomarker in COVID-19: a case series
APMIS, 129 (4), 237-238
DOI 10.1111/apm.13108, PubMed 33368687

Kåsine T, Dyrhol-Riise AM, Barratt-Due A, Kildal AB, Olsen IC, Nezvalova-Henriksen K, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Berg Å, Johannessen A, Heggelund L, Dahl TB, Halvorsen B, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR et al. (2021)
Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial
J Intern Med, 291 (2), 241-243
DOI 10.1111/joim.13377, PubMed 34411368

Lerum TV, Maltzahn NN, Aukrust P, Trøseid M, Henriksen KN, Kåsine T, Dyrhol-Riise AM, Stiksrud B, Haugli M, Blomberg B, Kittang BR, Johannessen A, Hannula R, Aballi S, Kildal AB, Eiken R, Dahl TB, Lund-Johansen F, Müller F, Rodriguez JR, Meltzer C, Einvik G, Ueland T, Olsen IC, NOR-SOLIDARITY Consortium et al. (2021)
Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9
Sci Rep, 11 (1), 23205
DOI 10.1038/s41598-021-02547-x, PubMed 34853380

Lorvik KB, Meyer-Myklestad MH, Kushekar K, Handeland C, Medhus AW, Lund-Iversen M, Stiksrud B, Kvale D, Dyrhol-Riise AM, Taskén K, Reikvam DH (2021)
Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4+ T Cells in HIV-Infected Immunological Non-Responders
Front Immunol, 12, 744155
DOI 10.3389/fimmu.2021.744155, PubMed 34691047

Sigfrid L, Cevik M, Jesudason E, Lim WS, Rello J, Amuasi J, Bozza F, Palmieri C, Munblit D, Holter JC, Kildal AB, Reyes LF, Russell CD, Ho A, Turtle L, Drake TM, Beltrame A, Hann K, Bangura IR, Fowler R, Lakoh S, Berry C, Lowe DJ, McPeake J, Hashmi M et al. (2021)
What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol
BMJ Open, 11 (3), e043887
DOI 10.1136/bmjopen-2020-043887, PubMed 33692181

Ueland T, Dyrhol-Riise AM, Woll BM, Holten AR, Petteresen F, Lind A, Dudman SG, Heggelund L, Holter JC, Aukrust P (2021)
Increased inflammatory markers reflecting fibrogenesis are independently associated with cardiac involvement in hospitalized COVID-19 patients
J Infect, 82 (5), 186-230
DOI 10.1016/j.jinf.2021.01.017, PubMed 33516748

Aamodt AH, Høgestøl EA, Popperud TH, Holter JC, Dyrhol-Riise AM, Tonby K, Stiksrud B, Quist-Paulsen E, Berge T, Barratt-Due A, Aukrust P, Heggelund L, Blennow K, Zetterberg H, Harbo HF (2021)
Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19
J Neurol, 268 (10), 3574-3583
DOI 10.1007/s00415-021-10517-6, PubMed 33743046

Publications 2020

Hoel H, Heggelund L, Reikvam DH, Stiksrud B, Ueland T, Michelsen AE, Otterdal K, Muller KE, Lind A, Muller F, Dudman S, Aukrust P, Dyrhol-Riise AM, Holter JC, Trøseid M (2020)
Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement
J Intern Med, 289 (4), 523-531
DOI 10.1111/joim.13178, PubMed 32976665

Hoel IM, Sviland L, Syre H, Dyrhol-Riise AM, Skarstein I, Jebsen P, Jørstad MD, Wiker H, Mustafa T (2020)
Diagnosis of extrapulmonary tuberculosis using the MPT64 antigen detection test in a high-income low tuberculosis prevalence setting
BMC Infect Dis, 20 (1), 130
DOI 10.1186/s12879-020-4852-z, PubMed 32050915

Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, Tonby K, Barratt-Due A, Sokolova M, Schjalm C, Chaban V, Kolderup A, Tran T, Tollefsrud Gjølberg T, Skeie LG, Hesstvedt L, Ormåsen V, Fevang B, Austad C, Müller KE, Fladeby C, Holberg-Petersen M, Halvorsen B, Müller F, Aukrust P et al. (2020)
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
Proc Natl Acad Sci U S A, 117 (40), 25018-25025
DOI 10.1073/pnas.2010540117, PubMed 32943538

Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE, Jenum S, Skeie LG, Nur S, Lind A, Opsand H, Enersen TB, Grøndahl R, Hermann A, Dudman S, Muller F, Ueland T, Mollnes TE, Aukrust P, Heggelund L, Holten AR, Dyrhol-Riise AM (2020)
Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19
Sci Rep, 10 (1), 21697
DOI 10.1038/s41598-020-78710-7, PubMed 33303843

Jøntvedt Jørgensen M, Jenum S, Tonby K, Mortensen R, Walzl G, Du Plessis N, Dyrhol-Riise AM (2020)
Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors
J Leukoc Biol, 110 (1), 177-186
DOI 10.1002/JLB.4A0720-409RR, PubMed 33155730

Mustafa T, Wergeland I, Baba K, Pathak S, Hoosen AA, Dyrhol-Riise AM (2020)
Mycobacterial antigens in pleural fluid mononuclear cells to diagnose pleural tuberculosis in HIV co-infected patients
BMC Infect Dis, 20 (1), 459
DOI 10.1186/s12879-020-05165-6, PubMed 32611401

Nore KG, Jørgensen MJ, Dyrhol-Riise AM, Jenum S, Tonby K (2020)
Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease
Front Immunol, 11, 579849
DOI 10.3389/fimmu.2020.579849, PubMed 33304347

Ueland T, Heggelund L, Lind A, Holten AR, Tonby K, Michelsen AE, Jenum S, Jørgensen MJ, Barratt-Due A, Skeie LG, Nordøy I, Aanensen Fraz MS, Quist-Paulsen E E, Pischke SE, Johal SK, Hesstvedt L, Bogen M, Fevang B, Halvorsen B, Müller F, Bekken GK, Mollnes TE, Dudman S, Aukrust P, Dyrhol-Riise AM et al. (2020)
Elevated plasma sTIM-3 levels in patients with severe COVID-19
J Allergy Clin Immunol, 147 (1), 92-98
DOI 10.1016/j.jaci.2020.09.007, PubMed 32971109

Ueland T, Holter JC, Holten AR, Müller KE, Lind A, Bekken GK, Dudman S, Aukrust P, Dyrhol-Riise AM, Heggelund L (2020)
Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure
J Infect, 81 (3), e41-e43
DOI 10.1016/j.jinf.2020.06.061, PubMed 32603675

Publications 2019

Hoel IM, Jørstad MD, Marijani M, Ruhwald M, Mustafa T, Dyrhol-Riise AM (2019)
IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting
Sci Rep, 9 (1), 3871
DOI 10.1038/s41598-019-40458-0, PubMed 30846768

Jørstad MD, Dyrhol-Riise AM, Aßmus J, Marijani M, Sviland L, Mustafa T (2019)
Evaluation of treatment response in extrapulmonary tuberculosis in a low-resource setting
BMC Infect Dis, 19 (1), 426
DOI 10.1186/s12879-019-4034-z, PubMed 31096926

Mortensen R, Clemmensen HS, Woodworth JS, Therkelsen ML, Mustafa T, Tonby K, Jenum S, Agger EM, Dyrhol-Riise AM, Andersen P (2019)
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice
Commun Biol, 2, 288
DOI 10.1038/s42003-019-0530-3, PubMed 31396568

Stiksrud B, Aass HCD, Lorvik KB, Ueland T, Trøseid M, Dyrhol-Riise AM (2019)
Activated dendritic cells and monocytes in HIV immunological nonresponders: HIV-induced interferon-inducible protein-10 correlates with low future CD4+ recovery
AIDS, 33 (7), 1117-1129
DOI 10.1097/QAD.0000000000002173, PubMed 30789356

Storm-Larsen C, Stiksrud B, Eriksen C, Nowak P, Holm K, Thalme A, Dyrhol-Riise AM, Brix S, Hov JR, Trøseid M (2019)
Microbial translocation revisited: targeting the endotoxic potential of gut microbes in HIV-infected individuals
AIDS, 33 (4), 645-653
DOI 10.1097/QAD.0000000000002087, PubMed 30531315

Tonby K, Mortensen R, Ruhwald M, Dyrhol-Riise AM, Jenum S (2019)
KLRG1-Expressing CD4 T Cells Are Reduced in Tuberculosis Patients Compared to Healthy Mycobacterium tuberculosis-Infected Subjects, but Increase With Treatment
J Infect Dis, 220 (1), 174-176
DOI 10.1093/infdis/jiz056, PubMed 30888024

Publications 2018

Habtamu M, Abebe M, Aseffa A, Dyrhol-Riise AM, Spurkland A, Abrahamsen G (2018)
In vitro analysis of antigen induced T cell-monocyte conjugates by imaging flow cytometry
J Immunol Methods, 460, 93-100
DOI 10.1016/j.jim.2018.06.014, PubMed 29981305

Jørstad MD, Marijani M, Dyrhol-Riise AM, Sviland L, Mustafa T (2018)
MPT64 antigen detection test improves routine diagnosis of extrapulmonary tuberculosis in a low-resource setting: A study from the tertiary care hospital in Zanzibar
PLoS One, 13 (5), e0196723
DOI 10.1371/journal.pone.0196723, PubMed 29742144

Orlien SMS, Ismael NY, Ahmed TA, Berhe N, Lauritzen T, Roald B, Goldin RD, Stene-Johansen K, Dyrhol-Riise AM, Gundersen SG, Morgan MY, Johannessen A (2018)
Unexplained chronic liver disease in Ethiopia: a cross-sectional study
BMC Gastroenterol, 18 (1), 27
DOI 10.1186/s12876-018-0755-5, PubMed 29439653

Quist-Paulsen E, Aukrust P, Kran AB, Dunlop O, Ormaasen V, Stiksrud B, Midttun Ø, Ueland T, Ueland PM, Mollnes TE, Dyrhol-Riise AM (2018)
High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections
J Neuroinflammation, 15 (1), 327
DOI 10.1186/s12974-018-1366-3, PubMed 30470234

Sane Schepisi M, Navarra A, Altet Gomez MN, Dudnyk A, Dyrhol-Riise AM, Esteban J, Giorgetti PF, Gualano G, Guglielmetti L, Heyckendorf J, Kaluzhenina A, Lange B, Lange C, Manika K, Miah J, Nanovic Z, Pontali E, Prego MR, Solovic I, Tiberi S, Palmieri F, Girardi E (2018)
Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study
Open Forum Infect Dis, 6 (1), ofy337
DOI 10.1093/ofid/ofy337, PubMed 30697572

Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, White RA, Winje BA (2018)
Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study
BMC Infect Dis, 18 (1), 587
DOI 10.1186/s12879-018-3468-z, PubMed 30453946

Publications 2017

Brekke K, Sommerfelt M, Ökvist M, Dyrhol-Riise AM, Kvale D (2017)
The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
BMC Infect Dis, 17 (1), 228
DOI 10.1186/s12879-017-2316-x, PubMed 28340570

Feruglio SL, Kvale D, Dyrhol-Riise AM (2017)
T Cell Responses and Regulation and the Impact of In Vitro IL-10 and TGF-β Modulation During Treatment of Active Tuberculosis
Scand J Immunol, 85 (2), 138-146
DOI 10.1111/sji.12511, PubMed 27862137

Prebensen C, Trøseid M, Ueland T, Dahm A, Sandset PM, Aaberge I, Waalen K, Dyrhol-Riise AM, Taskén K, Kvale D (2017)
Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial
PLoS One, 12 (5), e0176527
DOI 10.1371/journal.pone.0176527, PubMed 28464042

Publications 2016

Jensenius M, Winje BA, Blomberg B, Mengshoel AT, Lippe Bv, Hannula R, Bruun JN, Knudsen PK, Rønning JO, Heldal E, Dyrhol-Riise AM (2016)
Multidrug-resistant tuberculosis in Norway: a nationwide study, 1995-2014
Int J Tuberc Lung Dis, 20 (6), 786-92
DOI 10.5588/ijtld.15.0895, PubMed 27155182

Prebensen C, Lind A, Dyrhol-Riise AM, Kvale D (2016)
Regulation of Gag- and Env-Specific CD8+ T Cell Responses in ART-Naïve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy
PLoS One, 11 (4), e0153849
DOI 10.1371/journal.pone.0153849, PubMed 27128502

Stiksrud B, Lorvik KB, Kvale D, Mollnes TE, Ueland PM, Trøseid M, Taskén K, Dyrhol-Riise AM (2016)
Plasma IP-10 Is Increased in Immunological NonResponders and Associated With Activated Regulatory T Cells and Persisting Low CD4 Counts
J Acquir Immune Defic Syndr, 73 (2), 138-48
DOI 10.1097/QAI.0000000000001080, PubMed 27632144

Tonby K, Wergeland I, Lieske NV, Kvale D, Tasken K, Dyrhol-Riise AM (2016)
The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection
BMC Infect Dis, 16 (1), 599
DOI 10.1186/s12879-016-1938-8, PubMed 27776487

Wergeland I, Assmus J, Dyrhol-Riise AM (2016)
Cytokine Patterns in Tuberculosis Infection; IL-1ra, IL-2 and IP-10 Differentiate Borderline QuantiFERON-TB Samples from Uninfected Controls
PLoS One, 11 (9), e0163848
DOI 10.1371/journal.pone.0163848, PubMed 27685462

Publications 2015

Feruglio SL, Tonby K, Kvale D, Dyrhol-Riise AM (2015)
Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection
Clin Exp Immunol, 179 (3), 454-65
DOI 10.1111/cei.12468, PubMed 25313008

Lieske NV, Tonby K, Kvale D, Dyrhol-Riise AM, Tasken K (2015)
Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
PLoS One, 10 (11), e0141903
DOI 10.1371/journal.pone.0141903, PubMed 26544592

Prebensen C, Ueland T, Michelsen AE, Lind A, Pettersen FO, Mollnes TE, Aukrust P, Dyrhol-Riise AM, Kvale D (2015)
High MIP-1β Levels in Plasma Predict Long-Term Immunological Nonresponse to Suppressive Antiretroviral Therapy in HIV Infection
J Acquir Immune Defic Syndr, 69 (4), 395-402
DOI 10.1097/QAI.0000000000000617, PubMed 26115437

Riise AMD (2015)
Our Voices HIV: 30 years in Norway
Tidsskr. Nor. Laegeforen., 135 (19), 1769
DOI 10.4045/tidsskr.15.0785

Stiksrud B, Nowak P, Nwosu FC, Kvale D, Thalme A, Sonnerborg A, Ueland PM, Holm K, Birkeland SE, Dahm AE, Sandset PM, Rudi K, Hov JR, Dyrhol-Riise AM, Trøseid M (2015)
Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART
J Acquir Immune Defic Syndr, 70 (4), 329-37
DOI 10.1097/QAI.0000000000000784, PubMed 26258571

Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise AM (2015)
IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
Sci Rep, 5, 9223
DOI 10.1038/srep09223, PubMed 25783975

Wergeland I, Pullar N, Assmus J, Ueland T, Tonby K, Feruglio S, Kvale D, Damås JK, Aukrust P, Mollnes TE, Dyrhol-Riise AM (2015)
IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy
J Infect, 70 (4), 381-91
DOI 10.1016/j.jinf.2014.12.019, PubMed 25597826

Publications 2014

Eldholm V, Norheim G, von der Lippe B, Kinander W, Dahle UR, Caugant DA, Mannsåker T, Mengshoel AT, Dyrhol-Riise AM, Balloux F (2014)
Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient
Genome Biol, 15 (11), 490
DOI 10.1186/s13059-014-0490-3, PubMed 25418686

Pettersen PS, Brox IK, Naman E, Bruun JN, Dyrhol-Riise AM, Trøseid M, Johannessen A (2014)
Antiretroviral treatment failure predicts mortality in rural Tanzania
Int J STD AIDS, 26 (9), 633-9
DOI 10.1177/0956462414548460, PubMed 25122578

Pullar ND, Steinum H, Bruun JN, Dyrhol-Riise AM (2014)
HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study
BMC Infect Dis, 14, 667
DOI 10.1186/s12879-014-0667-0, PubMed 25515915

Pullar ND, Steinum H, Tonby K, Heggelund L, Leiva RA, Ofstad R, Bruun JN, Dyrhol-Riise AM (2014)
Low prevalence of positive interferon-gamma tests in HIV-positive long-term immigrants in Norway
Int J Tuberc Lung Dis, 18 (2), 180-7
DOI 10.5588/ijtld.13.0276, PubMed 24429310

Publications 2013

Feruglio SL, Trøseid M, Damås JK, Kvale D, Dyrhol-Riise AM (2013)
Soluble markers of the Toll-like receptor 4 pathway differentiate between active and latent tuberculosis and are associated with treatment responses
PLoS One, 8 (7), e69896
DOI 10.1371/journal.pone.0069896, PubMed 23875007

Gran G, Aßmus J, Dyrhol-Riise AM (2013)
Screening for latent tuberculosis in Norwegian health care workers: high frequency of discordant tuberculin skin test positive and interferon-gamma release assay negative results
BMC Public Health, 13, 353
DOI 10.1186/1471-2458-13-353, PubMed 23590619

Lind A, Brekke K, Sommerfelt M, Holmberg JO, Aass HC, Baksaas I, Sørensen B, Dyrhol-Riise AM, Kvale D (2013)
Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms
Vaccine, 31 (41), 4611-8
DOI 10.1016/j.vaccine.2013.07.037, PubMed 23906886

Publications 2011

Hesstvedt L, Wilhelmsen M, Mengshoel AT, Dyrhol-Riise AM (2011)
Two Norwegian patients with melioidosis presenting with bacteraemia and splenic and prostatic abscesses
J Travel Med, 18 (6), 418-21
DOI 10.1111/j.1708-8305.2011.00550.x, PubMed 22017720

Wergeland I, Assmus J, Dyrhol-Riise AM (2011)
T regulatory cells and immune activation in Mycobacterium tuberculosis infection and the effect of preventive therapy
Scand J Immunol, 73 (3), 234-42
DOI 10.1111/j.1365-3083.2010.02496.x, PubMed 21204895

Publications 2010

Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, Blomberg B, Haanshuus CG, Mørkve O (2010)
Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country
BMC Infect Dis, 10, 57
DOI 10.1186/1471-2334-10-57, PubMed 20210999

Publications 2009

Storla DG, Kristiansen I, Oftung F, Korsvold GE, Gaupset M, Gran G, Øverby AK, Dyrhol-Riise AM, Bjune GA (2009)
Use of interferon gamma-based assay to diagnose tuberculosis infection in health care workers after short term exposure
BMC Infect Dis, 9, 60
DOI 10.1186/1471-2334-9-60, PubMed 19432995

Publications 2008

Baba K, Dyrhol-Riise AM, Sviland L, Langeland N, Hoosen AA, Wiker HG, Mustafa T (2008)
Rapid and specific diagnosis of tuberculous pleuritis with immunohistochemistry by detecting Mycobacterium tuberculosis complex specific antigen MPT64 in patients from a HIV endemic area
Appl Immunohistochem Mol Morphol, 16 (6), 554-61
DOI 10.1097/PAI.0b013e31816c3f79, PubMed 18698260

Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM (2008)
Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts
PLoS One, 3 (7), e2788
DOI 10.1371/journal.pone.0002788, PubMed 18665218

Baba K, Pathak S, Sviland L, Langeland N, Hoosen AA, Asjo B, Dyrhol-Riise AM, Mustafa T (2008)
Real-time quantitative PCR in the diagnosis of tuberculosis in formalin-fixed paraffin-embedded pleural tissue in patients from a high HIV endemic area
Diagn Mol Pathol, 17 (2), 112-7
DOI 10.1097/PDM.0b013e31814ceac3, PubMed 18382372

Baba K, Sørnes S, Hoosen AA, Lekabe JM, Mpe MJ, Langeland N, Dyrhol-Riise AM (2008)
Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON TB-Gold interferon-gamma assay
BMC Infect Dis, 8, 35
DOI 10.1186/1471-2334-8-35, PubMed 18366633

Winje BA, Oftung F, Korsvold GE, Mannsåker T, Ly IN, Harstad I, Dyrhol-Riise AM, Heldal E (2008)
School based screening for tuberculosis infection in Norway: comparison of positive tuberculin skin test with interferon-gamma release assay
BMC Infect Dis, 8, 140
DOI 10.1186/1471-2334-8-140, PubMed 18928541

Publications 2006

Voltersvik P, Bostad L, Dyrhol-Riise AM, Eide GE, Røsok BI, Olofsson J, Asjö B (2006)
Cystatin A and HIV-1 p24 antigen expression in tonsillar lymphoid follicles during HIV-1 infection and during highly active antiretroviral therapy
J Acquir Immune Defic Syndr, 41 (3), 277-84
DOI 10.1097/01.qai.0000199234.77081.a2, PubMed 16540928

Wiker HG, Mustafa T, Målen H, Riise AM (2006)
Vaccine approaches to prevent tuberculosis
Scand J Immunol, 64 (3), 243-50
DOI 10.1111/j.1365-3083.2006.01815.x, PubMed 16918693

Publications 2003

Voltersvik P, Albrektsen G, Ulvestad E, Dyrhol-Riise AM, Sørensen B, Asjö B (2003)
Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia
J Acquir Immune Defic Syndr, 34 (4), 358-67
DOI 10.1097/00126334-200312010-00002, PubMed 14615653

Publications 2001

Dyrhol-Riise AM, Ohlsson M, Skarstein K, Nygaard SJ, Olofsson J, Jonsson R, Asjö B (2001)
T cell proliferation and apoptosis in HIV-1-infected lymphoid tissue: impact of highly active antiretroviral therapy
Clin Immunol, 101 (2), 180-91
DOI 10.1006/clim.2001.5102, PubMed 11683577

Dyrhol-Riise AM, Stent G, Røsok BI, Voltersvik P, Olofsson J, Asjö B (2001)
The Fas/FasL system and T cell apoptosis in HIV-1-infected lymphoid tissue during highly active antiretroviral therapy
Clin Immunol, 101 (2), 169-79
DOI 10.1006/clim.2001.5101, PubMed 11683576

Dyrhol-Riise AM, Voltersvik P, Berg OG, Olofsson J, Kleivbo S, Asjö B (2001)
Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization
AIDS Res Hum Retroviruses, 17 (7), 577-86
DOI 10.1089/088922201300119671, PubMed 11375053

Publications 2000

Dyrhol-Riise AM (2000)
Human immunodeficiency virus type I (HIV-1) infection andhighly active antiretroviral therapy: virus dynamics and immune reconstitution in blood and tonsillar tissue
Centre for Research in Virology, Department of Microbiology and Immunology, The Gade Institute, University of Bergen, Bergen, 1 b. (flere pag.)
BIBSYS 001595962, ISBN 82-7788-086-3

Dyrhol-Riise AM, Brantsaeter AB, Dunlop O, Baklien K, Skar AG, Asjö B, Bruun JN, Røsok BI (2000)
Early changes in peripheral blood T cell subsets induced by antiretroviral treatment of human immunodeficiency virus-1 positive individuals
Scand J Immunol, 51 (2), 195-201
DOI 10.1046/j.1365-3083.2000.00659.x, PubMed 10652164

Dyrhol-Riise AM, Voltersvik P, Røsok BI, Olofsson J, Asjö B (2000)
Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection
AIDS Res Hum Retroviruses, 16 (3), 191-201
DOI 10.1089/088922200309287, PubMed 10710207

Voltersvik P, Dyrhol-Riise AM, Bostad L, Røsok BI, Olofsson J, Asjö B (2000)
Changes in tonsillar tissue in early HIV-1 infection and during 3 years of antiretroviral therapy
APMIS, 108 (7-8), 539-50
DOI 10.1034/j.1600-0463.2000.d01-94.x, PubMed 11167551

Publications 1999

Dyrhol-Riise AM, Voltersvik P, Olofsson J, Asjö B (1999)
Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection
AIDS, 13 (17), 2365-76
DOI 10.1097/00002030-199912030-00008, PubMed 10597778